A Phase II Randomized Study of Oral CC-5013 Lenalidomide (Revlimid), an Antiangiogenic and Immunomodulatory Agent in Subjects With Stage IV Ocular Melanoma.

Trial Profile

A Phase II Randomized Study of Oral CC-5013 Lenalidomide (Revlimid), an Antiangiogenic and Immunomodulatory Agent in Subjects With Stage IV Ocular Melanoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jan 2017

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Eye neoplasms; Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 27 Feb 2012 Planned number of patients changed from 38 to 76 as reported by ClinicalTrials.gov.
    • 27 Feb 2012 Planned number of patients changed from 38 to 76 as reported by ClinicalTrials.gov.
    • 27 Feb 2012 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top